Scientists have created a vaccine containing monoclonal antibodies that are effective against several synthetic opioids, including carfentanil.
Researchers have demonstrated that a DNA vaccine tested in mice is effective at reducing accumulation of tau and beta-amyloid proteins associated with Alzheimer’s disease.
Interim results from a Phase III trial of DCVax®-L have revealed that the vaccine could be safe in glioblastoma patients and may extend survival.
AAN 2018: Additional biomarker and vaccine responses announced for ocrelizumab in multiple sclerosis
This week, the American Academy of Neurology (CA, USA) presented findings from two studies that investigate the impact of ocrelizumab in multiple sclerosis patients.
18 months on from the WHO’s declaration of a Public Health Emergency, we provide an update on Zika, including a research round-up and vaccine pipelines.
Is a Zika vaccine imminent? Martha Powell provides an overview of the current Zika vaccine candidates in human clinical trials and how these vaccines are being assessed.
Research presented at ASM Microbe has reported a Zika vaccine based on the NS1 protein can induce protective immunity in mouse models after a single dose.
In new research, the first live-attenuated Zika vaccine has been demonstrated to protected mice against the virus after a single dose.
This article reviews new vaccination protocols against glioblastoma, as well as new the prospect of novel combination therapies.
Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
In this study, the authors identified SDC-4 as a biomarker to predict clinical outcome using peripheral blood mononuclear cells obtained from patients with glioblastoma, a malignant brain tumor, who were treated with WT1 peptide vaccine.